Value-Based Price For Lilly’s Necitumumab Estimated Using Pre-Approval Cost Model
This article was originally published in The Pink Sheet Daily
Researchers present a model at the ASCO annual meeting for identifying cost-effective prices for drugs that have not yet reached the market. Oncology drug pricing and value was an important theme at the 2015 gathering.
Register for our free email digests: